This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, Mcevoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman J, CATIE Study Investigators.Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of tratment for chronic schizophrenia. American Journal of Psychiatry 163: 2080-2089, No. 12, Dec 2006
Freedman R, Carpenter Jr WT, Davis JM, Goldman HH, Tamminga CA, Thomas M.The costs of drugs for schizophrenia. American Journal of Psychiatry 163: 2029-2031, No. 12, Dec 2006
Rights and permissions
About this article
Cite this article
Perphenazine may be best bet in schizophrenia. Pharmacoecon. Outcomes News 521, 6 (2007). https://doi.org/10.2165/00151234-200705210-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705210-00016